Multiple Myeloma

Patient factors and access barriers are reshaping treatment sequencing and individualized care for relapsed multiple myeloma, Amandeep Godara, MBBS, said.

Five August FDA approvals introduced novel therapies across vaccines, neurology, oncology, myeloma, and dermatomyositis, despite some regulatory pushback.

The cereblon E3 ligase modulator, or CELMoD, also received a breakthrough therapy designation from the FDA.

Peter Forsberg, MD, discusses referral pathways, payer barriers, and expanding access to CAR T-cell and bispecific therapies.

Peter Forsberg, MD, discusses why health systems must adapt to expand equitable access to CAR T-cell and bispecific therapies.

Experts discussed innovations in oncology care, treatment access, pharmacy workflows, and patient outcomes.

The new MonumenTAL-6 combination data appear to exceed MajesTEC-9 numbers.

Hans Lee, MD, lays out the tradeoffs in travel, time off therapy, and who each option realistically fits when looking at CAR T-cell and bispecific therapies.

Moving to a subQ formulation makes sense, if you want to be 100% convenient for patients and the centers that treat them, explains Xavier Leleu, MD, PhD.

Coverage from the Institute for Value-Based Medicine session in Dallas, Texas, held May 21,2026.

This analysis, presented by Rahul Banerjee, MD, FACP, at EHA 2026, builds on data that supported the FDA’s March 2026 approval of teclistamab.

Swarup Kumar, MD, also details treating incarcerated patients with bispecifics and pursuing cure-focused therapy sequencing in myeloma.

Ajay K. Nooka, MD, MPH, explains why CD38 exposure complicates trial applicability, how MRD could speed approvals, and what a dex-free future looks like.

FDA clears hands-free on-body injector for isatuximab in multiple myeloma, cutting treatment time and reactions while matching IV efficacy.

Ajai Chari, MD, addresses myeloma’s future: personalized care, shared decision-making, and why striving for a functional cure matters now.

Tec-Dara showed higher MRD-negative CR rates and a 3-year PFS signal in high-risk relapsed/refractory MM, with durability still under longer-term follow-up.

Swarup Kumar, MD, discusses how myeloma programs can bridge gaps between academic innovation and community access for bispecific antibody therapy.

Mohit Narang, MD, discusses how community oncology practices can expand access to CAR T and bispecific therapies through better infrastructure and collaboration.

New research reveals complex treatment costs from MM strain patients and caregivers during active therapy, while pain goes undertreated at end of life.

The myeloma space has undergone tremendous transformation recently, says Prerna Mewawalla, MD, including CAR T-cell therapies and bispecific antibodies.

The lead investigator for SUCCESSOR-2 discusses the potency of a potential successor to pomalidomide in treatment of multiple myeloma, with survival outcomes that rival CAR T-cell therapy.

Ajai Chari, MD, unpacks resistance mechanisms, treatment sequencing, and why myeloma’s future may be brighter than anyone predicted.

Discussions highlighted implementing innovative treatments and ensuring patients treated in the community setting have equitable access to advanced therapeutics.

Swarup Kumar, MD, discusses how bispecific antibodies are pushing myeloma cure rates to 40%—and what clinicians must know about managing infections and CRS.

Researchers found major differences between smoldering myeloma risk tools, raising concerns about overtreatment and defining “high risk.”